Tianjin Pharmaceutical da Ren Tang Group Ltd 2022 AR2
The report outlines Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's financial and operational performance for the fiscal year 2022. The company rebranded from Tianjin Zhong Xin Pharmaceutical Group Corporation Limited to its current name to enhance its brand competitiveness and focus on traditional Chinese medicine. Key highlights include a 19% increase in revenue to approximately RMB 8,249 million and a 12% increase in profit attributable to equity holders to RMB 862 million. The company also optimized its organizational structure, integrated its marketing platforms, and expanded its research and development initiatives, including clinical studies on core products like Suxiao Jiuxin Wan.
Company: Tianjin Pharmaceutical da Ren Tang Group Ltd
Sector: Manufacturing
Country: China
Year: 2022
Type: AR2
Pages: 218
Tianjin Pharmaceutical da Ren Tang Group Ltd
The report outlines Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's financial and operational performance for the fiscal year 2022. The company rebranded from Tianjin Zhong Xin Pharmaceutical Group Corporation Limited to its current name to enhance its brand competitiveness and focus on traditional Chinese medicine. Key highlights include a 19% increase in revenue to approximately RMB 8,249 million and a 12% increase in profit attributable to equity holders to RMB 862 million. The company also optimized its organizational structure, integrated its marketing platforms, and expanded its research and development initiatives, including clinical studies on core products like Suxiao Jiuxin Wan.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
No data available